Health ❯ Patient Care

Treatment Efficacy

Survival Rates Clinical Outcomes Adverse Events Side Effects Quality of Life Clinical Studies Drug Combinations Weight Management Safety Profiles Clinical Remission Drug Response Adverse Reactions

Personalized mRNA Vaccine Halves Five‑Year Melanoma Recurrence Risk

Five‑year results show durable drops in metastasis with higher survival, leaving phase 3 confirmation plus manufacturing scale‑up as remaining needs.

Intellia’s Gene-Editing Drug Cuts HAE Attacks 87% in Phase 3 as FDA Filing Begins

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

Pluvicto Added to Standard Care Extends rPFS in PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

FDA Approves Papzimeos as First Therapy for Adult Recurrent Respiratory Papillomatosis

Nektar Therapeutics’ Rezpegaldesleukin Trial Success Sends Shares Up 150%